-Vonoprazan a potassium competitive acid blocker
-a first choice in treatment of GERD and Helicobacter.
-the inhibitory effect of vonoprazan is 300 times than other PPIs.
-In may 2022 , the FDA appaorved the use of vonoprazan in a co -packaged product containing amoxacillin and clarithromycin for the treatment of H.pylori infection.